Medidata Solutions Inc

Find Ratings Reports
MDSO : NASDAQ : Technology
$76.5 | %
Today's Range: 75.765 - 76.72
Avg. Daily Volume: 511600.0
09/22/17 - 4:00 PM ET

Financial Analysis


MEDIDATA SOLUTIONS INC's gross profit margin for the second quarter of its fiscal year 2017 is essentially unchanged when compared to the same period a year ago. The company managed to grow both sales and net income at a faster pace than the average competitor in its industry this quarter as compared to the same quarter a year ago. MEDIDATA SOLUTIONS INC is extremely liquid. Currently, the Quick Ratio is 3.14 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year.

At the same time, stockholders' equity ("net worth") has greatly increased by 40.72% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q2 FY17 Q2 FY16
Net Sales ($mil)137.41114.61
EBITDA ($mil)19.3914.91
EBIT ($mil)13.811.15
Net Income ($mil)8.256.21


Balance Sheet Q2 FY17 Q2 FY16
Cash & Equiv. ($mil)367.11318.28
Total Assets ($mil)888.86712.01
Total Debt ($mil)270.65256.35
Equity ($mil)442.79314.65


Profitability Q2 FY17 Q2 FY16
Gross Profit Margin80.7577.86
EBITDA Margin14.1113.01
Operating Margin10.049.73
Sales Turnover0.570.59
Return on Assets4.043.12
Return on Equity8.127.08
Debt Q2 FY17 Q2 FY16
Current Ratio3.373.75
Debt/Capital0.380.45
Interest Expense4.384.18
Interest Coverage3.152.66


Share Data Q2 FY17 Q2 FY16
Shares outstanding (mil)58.557.4
Div / share0.00.0
EPS0.140.11
Book value / share7.575.48
Institutional Own % n/a n/a
Avg Daily Volume638332.0497114.0

Valuation


BUY. MEDIDATA SOLUTIONS INC's P/E ratio indicates a significant premium compared to an average of 68.75 for the Health Care Technology industry and a significant premium compared to the S&P 500 average of 24.88. For additional comparison, its price-to-book ratio of 10.04 indicates a significant premium versus the S&P 500 average of 3.10 and a significant premium versus the industry average of 5.97. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium. Upon assessment of these and other key valuation criteria, MEDIDATA SOLUTIONS INC proves to trade at a premium to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
MDSO 122.58 Peers 68.75   MDSO 39.72 Peers 26.76

Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.

MDSO is trading at a significant premium to its peers.

 

Premium. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

MDSO is trading at a significant premium to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
MDSO 50.33 Peers 43.48   MDSO 0.80 Peers 0.91

Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations.

MDSO is trading at a significant premium to its peers.

 

Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

MDSO trades at a discount to its peers.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
MDSO 10.04 Peers 5.97   MDSO 58.97 Peers -148.57

Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

MDSO is trading at a significant premium to its peers.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

MDSO is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
MDSO 8.74 Peers 5.71   MDSO 20.89 Peers 34.24

Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

MDSO is trading at a significant premium to its industry.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

MDSO significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades